Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 310-290-3 | CAS number: 161907-80-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1992-06-02 to 1993-10-11
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- The study is well documented and performed according to GLP and generally valid and/or internationally accepted testing guidelines. As the percentage of B-TEGME in the test material is limited, it is not considered as a key study, but as a supporting study for the 90 day study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 993
- Report date:
- 1993
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Brake Fluid DOT 4 (lot 4200) containing B-TTEGME
- IUPAC Name:
- Brake Fluid DOT 4 (lot 4200) containing B-TTEGME
- Details on test material:
- - Name of test material (as cited in study report): Brake fluid 500 DOT 4
- Substance type: Borated Glycol Ether
- Physical state: Clear colourless liquid
- Analytical purity: 38% B-TTEGME
- Impurities (identity and concentrations): Confidential details on test material
- Composition of test material, percentage of components: Confidential details on test material
- Purity test date: Not provided
- Lot/batch No.: 4200 (SNC Sample No.); Indent 9450/9486; Toxicology Ref. No. ST91/267
- Expiration date of the lot/batch: Not provided
- Stability under test conditions: Not provided
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Manston, UK
- Age at study initiation: not reported
- Weight at study initiation: not reported
- Housing: single; polypropylene cages (pattern RB3R North Kent Plastics, Dartford);
- Diet: pelleted diet (Maintenance Diet No. 1, Expanded, Special Diets Services), ad libitum
- Water: public supply, ad libitum
- Acclimation period: No data
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-23
- Humidity (%): 45-70
- Air changes (per hr): Air conditioning
- Photoperiod (hrs dark / hrs light): 12/12
- No indications of bacterial contamination (each week a blood agar plate was exposed to air for one hour)
IN-LIFE DATES: From: 1992-06-02 To: 1992-07-17
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- Animals were dosed by oral gavage per day. Volumes administered were 0, 0.024, 0.142 and 0.943 ml/kg/day for the control, low, mid and high dose groups, corresponding to the 0, 25, 150 and 1000 mg brake fluid/kg bw/day dosages.
- Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- The test material was not analytically verified for the experiment as the material was used with a valid certificate of analysis.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0, 25, 150 and 1000 mg/kg bw/day
Basis:
other: brake fluid - oral gavage
- Remarks:
- Doses / Concentrations:
0, 9.5, 57 and 380 mg/kg bw/day
Basis:
other: B-TTEGME - oral gavage
- No. of animals per sex per dose:
- 5 males & 5 females/group
- Details on study design:
- - Dose selection rationale: Doses were selected based on a range finding study (No. 5249 from Sittingbourne research Centre).
- Rationale for animal assignment (if not random): Animals were allocated to treatment groups using a stratified body weight based computer program (ANALOC). Experimental animal numbers were then randomly allocated to animals.
- Rationale for selecting satellite groups: not applicable
- Post-exposure recovery period in satellite groups: not applicable
- Section schedule rationale (if not random): not applicable - Positive control:
- Not applicable
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily during the week and once daily on weekends and and holidays for clinical signs.
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT & FOOD CONSUMPTION: Yes (See Table 2 for food consumption)
- Time schedule for examinations: Body weight and food intake were measured weekly.
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Not applicable
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: during week 4 of the study
- Anaesthetic used for blood collection: Yes (CO2/O2 narcosis)
- Animals fasted: Yes (overnight)
- How many animals: all
- Parameters examined: white blood cells, red blood cells, haemoglobin, haematocrit, mean cell volume, mean cell haemoglobin, mean cell haemoglobin concentration, platelets, red cell distribution width, platelet distribution width, mean platelet volume, platocrit, differential white blood cell count, atypical lymphocytes, normocytes, microcytes.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: during week 4 of the study
- Animals fasted: Yes (overnight)
- How many animals: all
- Parameters examined: sodium, potassium, chloride, protein, albumin, urea, glucose, bilirubin, aspartate aminotransferase, alanine, aminotransferase, alkaline phosphatase, gamma globulin, cholesterol, triglycerides, calcium, inorganic phosphate, creatinine, albumin/globulin ratio.
URINALYSIS: Yes
- Time schedule for collection of urine: during week 4 of the study
- Metabolism cages used for collection of urine: glass metablows
- Animals fasted: Yes (food and water)
- Parameters examined: epithelial cells, tubular epithelium, leucocytes, erythrocytes, sperm cells, casts, bacteria, triphosphate crystals, ammonium phosphate crystals, oxalates, urates, mucus, osmolality, volume, colour, clarity, pH, protein, ketones, bilirubin
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY AND ORGAN WEIGHTS: Yes (see Table 3 for liver weight)
- A detailed post-mortem examination was performed. All gross abnormalities were recorded.
- Organ weights were measured: spleen, heart, brain, kidneys, liver, testes, adrenals, thymus, prostate, epidydimides.
HISTOPATHOLOGY: Yes (see Table 4 for liver changes)
- Histopathology was performed on tissues embedded in paraffin wax and stained with H&E stain.: Adrenals, brain, cervix, epididymides, eyes, heart, intestines, kidneys, liver, nerves (sciatic), ovaries, seminal vesicles, spinal cord, spleen, testes, and thymus. - Other examinations:
- Bone marrow smears were prepared from unfixed femur and fixed in methanol.
- Statistics:
- Two-way ANOVA analysis was performed where suitable. Williams' test was used to test for significance unless a dose-respons was not apparent in which case Dunnett's test was used. Wilcoxon 2 sample rank sum test was also used for haematology, clinical chemistry and urinalysis. Fisher's test (pairwise) was used for histopathology.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There were no treatment related deaths and no treatment related clinical signs.
One male animal (150 mg brake fluid/kg bw/day) was found dead on day 8 without previous clinical signs. The finding of patchy alveolar and bronchiolar oedema suggest that a portion of the dose might have entered the lungs. This death was considered to be due to a handling error.
BODY WEIGHT AND FOOD CONSUMPTION
No adverse effects on body weight.
Food intake was unaltered up to 150 mg brake fluid/kg bw/day. At 1000 mg brake fluid/kg there was a transient and slight but statistically significant decrease (-11%) in food consumption in males for the first two weeks of the study, which then was not apparent for the remainder of the study. No such effect was seen in females. See Table 2.
HAEMATOLOGY, CLINICAL CHEMISTRY andURINALYSIS
No treatment related adverse effects.
ORGAN WEIGHTS and GROSS PATHOLOGY
No treatment related adverse effects.
Liver weights were tabulated below (Table 3).
HISTOPATHOLOGY
No treatment related adverse effects up to 150 mg brake fluid/kg bw/day. The only findings was slight liver centrilobular hypertrophy in five males and three females dosed to 1000 mg brake fluid/kg bw/day (see Table 4). In the absence of any evidence of hepatotoxicity this was considered to reflect physiological adaptation to metabolism of a xenobiotic.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: Brake fluid A transient decrease in food consumption, and a very slight centrilobular hypertrophy in 3 females and all males at the 1000 mg/kg dose level, which was not considered to be adverse.
- Dose descriptor:
- NOAEL
- Effect level:
- >= 380 mg/kg bw/day (actual dose received)
- Sex:
- male/female
- Basis for effect level:
- other: B-TTEGME
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 2. Food consumption (g/animal/week)
Sex |
Week |
Control |
25 mg/kg bw/day |
150 mg/kg bw/day |
1000 mg/kg bw/day |
Males |
1 |
223.8 |
207.7 |
219.3 |
200.2 * |
|
2 |
219.1 |
210.2 |
212.6 |
194.1 * |
|
3 |
215.9 |
215.5 |
217.6 |
201.5 |
|
4 |
153.7 |
149.9 |
145.7 |
143.8 |
Females |
1 |
161.7 |
156.3 |
155.9 |
162.1 |
|
2 |
157.0 |
154.0 |
153.0 |
152.0 |
|
3 |
149.2 |
158.8 |
149.8 |
166.8 |
|
4 |
141.9 |
144.6 |
131.2 |
149.2 |
Sex |
Control |
25 mg/kg bw/day |
150 mg/kg bw/day |
1000 mg/kg bw/day |
Males (gram) |
11.82 |
11.70 |
11.80 |
12.64 |
% versus control |
|
99,0 |
99,8 |
106,9 |
Females (gram) |
7.52 |
7.70 |
7.36 |
7.73 |
% versus control |
|
102,4 |
97,9 |
102,8 |
Table 4. Incidences of centrilobular hypertrophy at histopathology
Sex |
Control |
25 mg/kg bw/day |
150 mg/kg bw/day |
1000 mg/kg bw/day |
Males |
0/5 |
0/5 |
0/5 |
5/5 ** |
Females |
0/5 |
0/5 |
0/5 |
3/5 |
** p < 0.01 significance of difference with control (Fisher’s test)
Applicant's summary and conclusion
- Conclusions:
- NOAEL: 1000 mg brake fluid/kg bw/day or greater as determined in a 28-day repeated dose toxicity study, corresponding with a NOAEL of 380 mg B-TTEGME/kg bw/day.
- Executive summary:
Brake Fluid DOT 4 is considered to have a similar toxicological profile as B-TTEGME. Brake fluid containing 38% B-TTEGME (of which 17% B-TEGME) was administered to groups of five rats/sex at doses of 0, 25, 150 and 1000 mg/kg/day for 28 days, corresponding to 0, 9.5, 57 and 380 mg B-TTEGME/kg bw/day. This did not result in clinical signs, effects on body weight, clinical chemistry, haematology, gross pathology, organ weight and urinalysis changes. The only finding related to treatment histologically was a very slight hepatocellular centrilobular hypertrophy in three females and five males at 1000 mg/kg bw/day. Considering the mild nature of the finding, and in the absence of any other relevant treatment related effect, this was not considered to constitute an adverse effect. The No Observed Adverse Effect Level (NOAEL) was therefore considered to be 380 mg B-TTEGME/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.